To take action or make you part of a business agreement (for example.B tenants, retailers, tenants, free trade customers or any other similar agreement) BOTHELL, Wash., Jan. 08, 2018 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today that it has compared a European patent and that a biopharmaceutical company is focusing on developing innovative therapeutic antibodies to treat migraine. has entered into an obale license agreement with Teva Pharmaceuticals International GmbH. By this agreement, Alder`s appeal will be brought following opposition proceedings before the European Patent Office concerning Teva`s European Patent No. 1. 1957106 B1 with respect to calcitonin-related peptide antibodies (CGRP) and clarity on Alder`s freedom to develop, produce and commercialize eptinezumab, its primary migraine prevention candidate. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements regarding: the further development and clinical, therapeutic and commercial potential of eptinezumab; the commercialization of eptinezumab; and the expected benefits to Alder under the above-mentioned transaction and license agreement and the parties` commitments. Words such as “becoming”, “providing”, “clarity”, “freedom”, “providing”, “potentially” or other similar expressions characteristic of forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, all statements relating to expectations, forecasts or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements contained in this press release are based on Alder`s plans, assumptions, beliefs, expectations, estimates and forecasts and involve significant risks and uncertainties. . .